Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer

• Autores principales: Fumihiko Ando (Autor), Takeru Kashiwada (Autor), Shoko Kuroda (Autor), Takenori Fujii (Autor), Ryotaro Takano (Autor), Yoshishige Miyabe (Autor), Shinobu Kunugi (Autor), Takashi Sakatani (Autor), Akihiko Miyanaga (Autor), Tomoko Asatsuma-Okumura (Autor), Masaaki Hashiguchi (Autor), Yoshikazu Kanazawa (Autor), Ryuji Ohashi (Autor), Hiroshi Yoshida (Autor), Masahiro Seike (Autor), Akihiko Gemma (Autor), Yoshiko Iwai (Autor)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

BackgroundThe tumor microenvironment (TME) impacts the therapeutic efficacy of immune checkpoint inhibitors (ICIs). No liquid biomarkers are available to evaluate TME heterogeneity. Here, we investigated the clinical significance of PD-1-binding soluble PD-L1 (bsPD-L1) in gastric cancer (GC) patient...